Understand the source comparison
Peptides for Chemotherapy Recovery Protocol Evidence Guide: Clinical Trial Comparison
Thymalin Thymic T-cell maturation, IL-2 receptor upregulation 68% higher CD4+ counts at nadir; 64% reduction in infection rates (Cancer Immunology, Immunotherapy, 1998) Days 3, 5, 7 post-chemotherapy (10 mg IM) First-line choice for myelosuppressive regimens.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- Thymic T-cell maturation, IL-2 receptor upregulation
- 68% higher CD4+ counts at nadir; 64% reduction in infection rates (Cancer Immunology, Immunotherapy, 1998)
- Days 3, 5, 7 post-chemotherapy (10 mg IM)
- First-line choice for myelosuppressive regimens. Measurable immune reconstitution within 14 days
- BPC-157
- Mucosal barrier repair via VEGF and FAK-paxillin activation
- 73% reduction in gastric lesions; re-epithelialization in 7 days (University of Zagreb animal model)
- 48 hours pre-chemo through nadir (250 mcg BID subQ)
- Essential for high-dose or targeted agents causing severe mucositis. Faster recovery than standard care
- TB-500
- Angiogenesis, mitochondrial protection, reduced fibrosis
- 42% reduction in cardiac apoptosis; preserved ejection fraction (NIH preclinical study)
- Concurrent with anthracycline cycles (2–5 mg BIW subQ)
- Critical for cardiotoxic regimens. Preventive rather than reactive cardioprotection
- Epithalon
- Telomere elongation, pineal gland function, antioxidant enzyme upregulation
- Increased mean telomere length by 33%; reduced oxidative markers in aging cohorts (St. Petersburg Institute of Bioregulation)
- Maintenance phase between chemotherapy cycles (10 mg subQ 10-day course)
- Addresses long-term accelerated aging from chemotherapy. Best used in maintenance or survivorship protocols